KORU Medical Systems, Inc. (KRMD) Balance Sheet

The shrinking equity base from $19.1M in 2024Q1 to $16.9M in 2026Q1 reflects the accumulated deficit deepening from -$25.2M to -$32.8M, which points to cumulative losses absorbing paid-in capital. The late-period recovery in equity to $18.1M in 2026Q2 is consistent with the single profitable quarter, but one quarter is insufficient to confirm a durable reversal. Investors should monitor whether earnings sustain positive retained earnings momentum.

Debt reduction without any evident refinancing event suggests the company is amortizing obligations from operating cash rather than adding borrowings. A D/E ratio under 0.25 leaves limited refinancing risk on the reported figures. The analytical question is whether repayment capacity remains intact given the intermittent free cash flow generation visible in the cash flow data.

A current ratio above 2.0 indicates ample short-term coverage, though the decline from 4.01 shows liquidity cushion has been partially consumed. Cash balances have remained relatively flat, implying the decline reflects rising current liabilities rather than cash depletion. Liquidity appears adequate for near-term operations, but the trend warrants monitoring alongside working capital swings.

The low goodwill balance indicates the asset base is largely organic rather than built through acquisitions, reducing impairment exposure. PP&E stability around $7M, combined with capex that was episodic and concentrated in 2024Q3, suggests a manufacturing footprint that is not expanding aggressively. The 2026Q2 goodwill increase to $1.7M from roughly $0.7M warrants a closer look at the underlying transaction, as the reported figures do not disclose its origin.